大和:重申中國海外發展(0688.HK)買入評級 目標價34.4港元
大和發表研究報吿指,中國海外發展(0688.HK)去年基本純利按年升10.9%至380億元人民幣,符合預期,公司去年淨利率達20.5%,為內房主要企業中最高,認為其財務狀況持續跑贏同行,有助面對未來的行業挑戰,料今年底其資產淨值為每股43港元,維持目標價34.4港元,重申買入評級。
大和表示,相信公司未來有不少中國辦公室目標數量的增加空間,這些因素將有助公司未來數年的經常性收入,留意到公司的每股派息持續上升,預期今年的股息率為6.8%,認為公司進行股份回購為正面因素,亦對股東有利。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.